

Policy Name Romiplostim (Nplate)	Policy Number MP-RX-FP-63-23	Scope <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth
Service Category <input type="checkbox"/> Anesthesia <input type="checkbox"/> Surgery <input type="checkbox"/> Radiology Procedures <input type="checkbox"/> Pathology and Laboratory Procedures <input type="checkbox"/> Medicine Services and Procedures <input type="checkbox"/> Evaluation and Management Services <input type="checkbox"/> DME/Prosthetics or Supplies <input checked="" type="checkbox"/> Part B DRUG		
Service Description <p>This document addresses the use of Romplostim (Nplate), a drug approved by the Food and Drug Administration (FDA) for the treatment of children and adults with immune thrombocytopenia, an autoimmune disorder that can cause uncontrolled bleeding if left untreated..</p> <p>Background Information</p> <p>Immune thrombocytopenia (ITP) is also called idiopathic thrombocytopenia purpura and immune thrombocytopenia purpura, which is an acquired autoimmune disorder characterized by low platelet counts caused by autoantibodies against platelet antigens. According to the National Institutes of Health, ITP occurs in approximately 1 in every 16,000 adults, causing unusual bruising or bleeding due to an abnormally low number of platelets in the blood.</p> <p>Nplate is FDA approved for the treatment of thrombocytopenia in individuals with ITP who had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.</p> <p>Nplate is FDA indicated for the following:</p> <ul style="list-style-type: none"> • Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. • Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. • Adults and pediatrics (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]). <p>Limitations of Use per label:</p> <ul style="list-style-type: none"> • Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP • Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding • Nplate should not be used in an attempt to normalize platelet counts. <p>Per specialty committee consensus opinion, ongoing treatment with Nplate (romiplostin) may be used to maintain an adequate platelet count (50 – 100 X 10⁹/L) to decrease the risk of bleeding. For platelet count</p>		

Policy Name	Policy Number	Scope
Romiplostim (Nplate)	MP-RX-FP-63-23	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth
<p>greater than 100,000/mm³, dose adjustments can be made using a cut-off platelet level of 100,000/mm³ as a substitute for 200,000/mm³ in the FDA dosage and administration recommendations.</p> <p>The NCCN Drugs and Biologics Compendium and NCCN Clinical Practice Guideline offers a Category 2A recommendation for the treatment of individuals with lower risk MDS disease with severe or refractory thrombocytopenia using romiplostim following disease progression or no response to hypomethylating agents, immunosuppressive therapy, or clinical trial. “Lower risk defined as IPSS-R (Very Low, Low, Intermediate), IPSS (Low/Intermediate-1), WPSS (Very low, low, intermediate)”. NCCN also provides a 2A recommendation for use of Nplate in chemotherapy-induced thrombocytopenia with the goal of allowing resumption of chemotherapy regimen when the benefits outweigh the risks.</p> <p>Approved Indications</p> <ul style="list-style-type: none"> A. Patients with Immune Thrombocytopenia (ITP) B. Myelodysplastic syndrome (MDS) C. Patients with Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS) D. Chemotherapy-induced thrombocytopenia (CIT) <p>Other Uses</p> <ul style="list-style-type: none"> A. N/A 		

Medical Policy

Healthcare Services Department

Policy Name	Policy Number	Scope
Romiplostim (Nplate)	MP-RX-FP-63-23	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPCS	Description
J2796	Injection, romiplostim, 10 micrograms [Nplate]

ICD-10	Description
D46.0-D46.9	Myelodysplastic syndromes
D69.3	Immune thrombocytopenic purpura
D69.41-D69.49	Other primary thrombocytopenia

Medical Necessity Guidelines

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Clinical Criteria

A. Criteria For Initial Approval

- i. Individual has a diagnosis of immune (idiopathic) thrombocytopenia (ITP) and the following are met
 - a. Documentation is provided that individual has a platelet count of less than 30 x 10⁹/L or active bleeding (ASH, 2011; Hicks et al., 2014); AND
 - b. Individual has had a prior trial and insufficient response to one of the following confirmed:
 - 1. Corticosteroids; OR
 - 2. Immunoglobulins (for example IVIg or anti-D); OR
 - 3. Splenectomy

OR

- ii. Individual has a diagnosis of Myelodysplastic Syndrome (MDS) and the following are met
 - a. Documentation is provided that individual has a diagnosis of lower risk myelodysplastic syndrome (MDS) [Lower risk defined as IPSS-R (Very Low, Low, Intermediate), IPSS (Low/Intermediate-1), WPSS (Very low, low, intermediate)] (NCCN 2A); AND
 - b. Individual has severe or refractory thrombocytopenia following disease progression or no response to hypomethylating agents or immunosuppressive therapy

OR

- iii. Individual has a diagnosis of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS) and the following are met
 - a. Individual a diagnosis of Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS] (i.e., acute exposure to myelosuppressive doses of radiation); AND
 - b. Individual has suspected or confirmed exposure to radiation levels greater than 2 gray (Gy)

OR

- iv. Individual has a diagnosis of Chemotherapy Induced Thrombocytopenia (CIT) and the following are met
 - a. Individual has demonstrated a response to therapy as confirmed by increased platelet counts; AND
 - b. Continuation of treatment is to maintain an adequate platelet count (100 - 150 X 10⁹/L) to allow for the resumption of chemotherapy regimen as appropriate

B. Criteria For Continuation of Therapy

- i. Individual has a diagnosis of ITP and the following are met:

Policy Name	Policy Number	Scope
Romiplostim (Nplate)	MP-RX-FP-63-23	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth
<ul style="list-style-type: none"> a. Documentation is provided that individual has demonstrated a response to therapy as confirmed by increased platelet counts; AND b. Continuation of treatment is to maintain an adequate platelet count (50 – 100 X 10⁹/L)* to decrease the risk of bleeding. ii. Continuation requests for MDS may be approved if the following criteria are met: <ul style="list-style-type: none"> a. Documentation is provided that individual has demonstrated a clinically significant response to therapy, such as an increase in platelet counts, decrease in bleeding events, or reduction in need for platelet transfusions. iii. Continuation requests for CIT may be approved if the following criteria are met: <ul style="list-style-type: none"> a. Individual has a diagnosis of CIT and the following are met: <ol style="list-style-type: none"> 1. Individual has demonstrated a response to therapy as confirmed by increased platelet counts; AND 2. Continuation of treatment is to maintain an adequate platelet count (100 - 150 X 10⁹/L) to allow for the resumption of chemotherapy regimen as appropriate. <p>C. Authorization Duration</p> <ul style="list-style-type: none"> i. Approval Duration for ITP: <ul style="list-style-type: none"> a. Initial Approval Duration: : 6 months b. Reauthorization Approval Duration: 12 month ii. Approval Duration for MDS <ul style="list-style-type: none"> a. Initial Approval Duration: 6 months b. Reauthorization Approval Duration: 12 months iii. Approval Duration for HS-ARS: 1 single administration per episode iv. Approval Duration for CIT <ul style="list-style-type: none"> a. Initial Approval Duration: 6 months b. Reauthorization Approval Duration: 12 months <p>D. Conditions Not Covered</p> <p><i>Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):</i></p> <ul style="list-style-type: none"> i. Individual is using to normalize platelet counts; OR ii. Individual is requesting for the treatment of low platelet count caused by any condition other than those conditions listed above; OR iii. When the above criteria are not met and for all other indications 		

Medical Policy

Healthcare Services Department

Policy Name Romiplostim (Nplate)	Policy Number MP-RX-FP-63-23	Scope <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth								
Limits or Restrictions A. Quantity Limitations <i>Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.</i> <table border="1" data-bbox="246 695 1464 842"> <thead> <tr> <th data-bbox="246 695 857 732">Drug</th> <th data-bbox="857 695 1464 732">Limit</th> </tr> </thead> <tbody> <tr> <td data-bbox="246 732 857 770">N/A</td> <td data-bbox="857 732 1464 770">N/A</td> </tr> <tr> <th colspan="2" data-bbox="246 770 1464 808">Exceptions</th> </tr> <tr> <td colspan="2" data-bbox="246 808 1464 842">N/A</td> </tr> </tbody> </table>			Drug	Limit	N/A	N/A	Exceptions		N/A	
Drug	Limit									
N/A	N/A									
Exceptions										
N/A										

Policy Name	Policy Number	Scope
Romiplostim (Nplate)	MP-RX-FP-63-23	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth

Reference Information

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2023. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: April 4, 2023
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Hicks LK, Bering H, Carson KR, et al. Five hematologic tests and treatments to question. Blood. 2014; 124(24):3524-3528. Available from: <http://www.bloodjournal.org/content/bloodjournal/124/24/3524.full.pdf?sso-checked=true>.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2023; Updated periodically.
6. NCCN Clinical Practice Guidelines in Oncology™. © 2022 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on April 4, 2023.
 - a. Hematopoietic Growth Factors. V2.2023. Revised March 6, 2023.
 - b. Myelodysplastic Syndromes. V1.2023. Revised September 12, 2022.
7. Neunert C, Terrell DR, Arnold DM, et al. The American Society of Hematology (ASH) 2019 evidence-based practice guideline for immune thrombocytopenia. Blood Adv. 2019; 3(23):3829-3866. Available from: <https://ashpublications.org/bloodadvances/article/3/23/3829/429213/American-Society-of-Hematology-2019-guidelines-for>. Accessed on: April 4, 2023.
8. DeSouza S, Angelini D. Updated guidelines for immune thrombocytopenic purpura: Expanded management options. Cleveland Clinic Journal of Medicine. 2021; 88(12):664668-3866. Available from: <https://www.ccm.org/content/88/12/664#sec-1>.

Medical Policy

Healthcare Services Department

Policy Name Romiplostim (Nplate)	Policy Number MP-RX-FP-63-23	Scope <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth
--	--	--

Policy History

Revision Type	Summary of Changes	P&T Approval Date	MPCC Approval Date
Policy Inception	Elevance Health's Medical Policy adoption.	N/A	11/30/2023

Revised: 5/16/2023